| Trial ID: | L7319 |
| Source ID: | NCT03234751
|
| Associated Drug: |
Continous Iv Infusion Of Nesiritide
|
| Title: |
Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects
|
| Acronym: |
BNP3
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes
|
| Interventions: |
DRUG: Continous IV infusion of Nesiritide|DRUG: Hyperinsulinemic euglycemic clamp|DRUG: Placebo
|
| Outcome Measures: |
Primary: IV infusion of nesiritide at a 3pmol/kg rate, Average changes in glucose disposal rates (GDR) and endogenous glucose production (EGP) from baseline corrected for body weight at steady state of the clamp during the high- and low-dose portions., 48 hours |
|
| Sponsor/Collaborators: |
Sponsor: AdventHealth Translational Research Institute
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
6
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2017-07-13
|
| Completion Date: |
2020-02-19
|
| Results First Posted: |
|
| Last Update Posted: |
2020-03-10
|
| Locations: |
Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, 32804, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03234751
|
